Sugi Predict

Sugi Predict / Compounds / SCHEMBL1865629

SCHEMBL1865629

SCHEMBL1865629

CCC1CC=C(c2cc(C3CNS(=O)(=O)NC3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 18/20 0.54
▸ KIT P10721 6/20 0.45
▸ CYP2C19 P33261 1/20 0.42
▸ BMPR1B O00238 2/20 0.41
▸ PLK4 O00444 2/20 0.41
▸ STK25 O00506 2/20 0.41
▸ RIOK3 O14730 2/20 0.41
▸ CHEK1 O14757 2/20 0.41
▸ GAK O14976 2/20 0.41
▸ DCLK1 O15075 2/20 0.41
▸ MUSK O15146 2/20 0.41
▸ EPHB6 O15197 2/20 0.41
▸ PDPK1 O15530 2/20 0.41
▸ MAP3K13 O43283 2/20 0.41
▸ DAPK3 O43293 2/20 0.41
▸ MAP3K7 O43318 2/20 0.41
▸ NUAK1 O60285 2/20 0.41
▸ JAK2 O60674 2/20 0.41
▸ ULK1 O75385 2/20 0.41
▸ ERN1 O75460 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12408130 0.86 CSF1R (0.46) CSF1RKITCYP2C19BMPR1BPLK4
SCHEMBL1856332 0.86 CSF1R (0.72) CSF1RKITCYP2C19
SCHEMBL13105935 0.79 CSF1R (0.73) CSF1RKITCYP2C19BMPR1BPLK4
SCHEMBL12422668 0.78 CSF1R (0.57) CSF1RKITCYP2C19NTRK1LCK
SCHEMBL13096400 0.78 CSF1R (0.59) CSF1RKITCYP2C19BMPR1BPLK4
SCHEMBL13096401 0.77 CSF1R (0.73) CSF1RKITCYP2C19NTRK1LCK
SCHEMBL14542959 0.77 CSF1R (0.62) CSF1RKITCYP2C19BMPR1BPLK4
SCHEMBL1860032 0.77 CSF1R (0.74) CSF1RKITCYP2C19BMPR1BPLK4
SCHEMBL13105557 0.77 CSF1R (0.72) CSF1RKITCYP2C19BMPR1BPLK4
SCHEMBL3089789 0.76 CSF1R (0.72) CSF1RKITCYP2C19NTRK1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9296726-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2016-03-29 — — US disclosed
US-20150051196-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2015-02-19 — — US disclosed
US-8895584-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2014-11-25 — — US disclosed
US-20140243382-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2014-08-28 — — US disclosed
US-8759347-B2 Inhibitors of C-FMS kinase JANSSEN PHARMACEUTICA NV (BE) 2014-06-24 — — US disclosed
US-20130281475-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2013-10-24 — — US disclosed
US-8481564-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2013-07-09 — — US disclosed
US-20110195960-A1 INHIBITORS OF C-FMS KINASE ILLIG CARL R 2011-08-11 — — US disclosed
US-20110195960-A1 INHIBITORS OF C-FMS KINASE ILLIG CARL R 2011-08-11 — — US disclosed
US-7973035-B2 Inhibitors of C-FMS kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2011-07-05 — — US disclosed
US-7973035-B2 Inhibitors of C-FMS kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2011-07-05 — — US disclosed
EP-2021335-B1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2011-05-25 — — EP disclosed
EP-2021335-B1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2011-05-25 — — EP disclosed
US-20080275031-A1 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent ILLIG CARL R 2008-11-06 — — US disclosed
US-7414050-B2 e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent JANSSEN PHARMACEUTICA, N.V. (BE) 2008-08-19 — — US disclosed
WO-2007124316-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-01 — — WO disclosed
US-20070249593-A1 e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281475-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES CSF1R 59/4885KIT 108/4885CYP2C19 2319/4885
US-20070249593-A1 e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent MUSK, CHUK, PNCK CSF1R 249/4885KIT 119/4885CYP2C19 1820/4885
US-20150051196-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES CSF1R 59/4885KIT 108/4885CYP2C19 2319/4885
US-20140243382-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES CSF1R 59/4885KIT 108/4885CYP2C19 2319/4885
US-20110195960-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES CSF1R 59/4885KIT 108/4885CYP2C19 2319/4885
US-20080275031-A1 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent MUSK, CHUK, CAMK4 CSF1R 249/4885KIT 214/4885CYP2C19 1883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.